Rapid Identification of Cell-Specific, Internalizing RNA Aptamers with Bioinformatics Analyses of a Cell-Based Aptamer Selection
暂无分享,去创建一个
Thomas Bair | Paloma H. Giangrande | William H. Thiel | William H Thiel | Mark A. Behlke | W. Thiel | P. Giangrande | M. Behlke | Justin P. Dassie | Xiuying Y. Liu | K. Stockdale | F. Miller | T. Bair | A. S. Peek | Andrew S. Peek | Xiuying Liu | Katie R. Stockdale | Justin Dassie | Francis J. Miller | Justin Dassie
[1] K Taira,et al. Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease. , 2000, European journal of biochemistry.
[2] B. Sullenger,et al. Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. , 2007, Oligonucleotides.
[3] Andrea Rentmeister,et al. Cell-Specific Aptamers as Emerging Therapeutics , 2011, Journal of nucleic acids.
[4] L. Gold,et al. Isolation of high-affinity RNA ligands to HIV-1 integrase from a random pool. , 1995, Virology.
[5] Bertrand Tavitian,et al. Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase , 2005, PLoS biology.
[6] Weihong Tan,et al. Identification of liver cancer-specific aptamers using whole live cells. , 2008, Analytical chemistry.
[7] L. J. Maher,et al. Selection and Characterization of an RNA Decoy for Transcription Factor NF-κB† , 1999 .
[8] J Charlton,et al. Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library. , 1997, Biochemistry.
[9] H. U. Göringer,et al. Combinatorial selection of high affinity RNA ligands to live African trypanosomes. , 1999, Nucleic acids research.
[10] Ying-Fon Chang,et al. Tenascin-C Aptamers Are Generated Using Tumor Cells and Purified Protein* , 2001, The Journal of Biological Chemistry.
[11] Michael Zuker,et al. Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information , 1981, Nucleic Acids Res..
[12] Walter Fontana,et al. Fast folding and comparison of RNA secondary structures , 1994 .
[13] D. S. Coffey,et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.
[14] R. Landgraf,et al. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[15] Yufei Huang,et al. Mechanism of ribose 2'-group discrimination by an RNA polymerase. , 1997, Biochemistry.
[16] M. Famulok,et al. Discriminatory aptamer reveals serum response element transcription regulated by cytohesin-2. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[17] L. Gold,et al. A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[18] J. M. Healy,et al. Complex Target SELEX , 2008 .
[19] J. Szostak,et al. In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.
[20] B. Sullenger,et al. In vivo selection of tumor-targeting RNA motifs , 2009, Nature chemical biology.
[21] William H. Thiel,et al. Isolation and Optimization of Murine IL-10 Receptor Blocking Oligonucleotide Aptamers Using High-throughput Sequencing. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[22] Gerhard Ziemer,et al. CELL-SELEX: Novel Perspectives of Aptamer-Based Therapeutics , 2008, International journal of molecular sciences.
[23] B. Sullenger,et al. RNA aptamers as reversible antagonists of coagulation factor IXa , 2002, Nature.
[24] L. Gold,et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.
[25] L. Cerchia,et al. Targeting cancer cells with nucleic acid aptamers. , 2010, Trends in biotechnology.
[26] Paloma H. Giangrande,et al. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers , 2012, Nucleic acids research.
[27] James O McNamara,et al. Targeted inhibition of αvβ3 integrin with an RNA aptamer impairs endothelial cell growth and survival , 2005 .
[28] J. McNamara,et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. , 2008, The Journal of clinical investigation.
[29] J. Nevins,et al. Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia , 2007, Proceedings of the National Academy of Sciences.
[30] S. Barth,et al. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. , 2008, Current cancer drug targets.
[31] Peter F. Stadler,et al. ViennaRNA Package 2.0 , 2011, Algorithms for Molecular Biology.
[32] R. Sousa,et al. A mutant T7 RNA polymerase as a DNA polymerase. , 1995, The EMBO journal.
[33] A. Barclay,et al. Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function. , 1998, Journal of immunology.
[34] James O McNamara,et al. Nucleotide bias observed with a short SELEX RNA aptamer library. , 2011, Nucleic acid therapeutics.
[35] L. J. Maher,et al. Selection and characterization of an RNA decoy for transcription factor NF-kappa B. , 1999, Biochemistry.
[36] A D Ellington,et al. Selection and design of high-affinity RNA ligands for HIV-1 Rev. , 1993, Gene.
[37] L. Gold,et al. High affinity ligands from in vitro selection: complex targets. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[38] H. Schluesener,et al. Systematic Evolution of a DNA Aptamer Binding to Rat Brain Tumor Microvessels , 2001, The Journal of Biological Chemistry.
[39] J. McCaskill. The equilibrium partition function and base pair binding probabilities for RNA secondary structure , 1990, Biopolymers.
[40] C H Heldin,et al. Inhibitory DNA ligands to platelet-derived growth factor B-chain. , 1996, Biochemistry.
[41] Li Li,et al. Label-free aptamer-based colorimetric detection of mercury ions in aqueous media using unmodified gold nanoparticles as colorimetric probe , 2009, Analytical and bioanalytical chemistry.
[42] B. Tavitian,et al. Differential SELEX in Human Glioma Cell Lines , 2009, PloS one.
[43] Doris Chen,et al. Monitoring Genomic Sequences during SELEX Using High-Throughput Sequencing: Neutral SELEX , 2010, PloS one.
[44] T. Böhm,et al. Controlling small guanine–nucleotide-exchange factor function through cytoplasmic RNA intramers , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[45] J. McNamara,et al. Degradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma-contaminated cell culture media. , 2012, Nucleic acid therapeutics.
[46] Weihong Tan,et al. Selection of DNA ligands for protein kinase C-delta. , 2006, Chemical communications.
[47] Seung Soo Oh,et al. Quantitative selection of DNA aptamers through microfluidic selection and high-throughput sequencing , 2010, Proceedings of the National Academy of Sciences.
[48] P. Giangrande,et al. Therapeutic applications of DNA and RNA aptamers. , 2009, Oligonucleotides.
[49] Hui Chen,et al. Molecular recognition of acute myeloid leukemia using aptamers , 2008, Leukemia.
[50] J. McNamara,et al. Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. , 2005, Biochemical and biophysical research communications.
[51] J. McNamara,et al. Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. , 2011, Nucleic acid therapeutics.
[52] Yi Xiao,et al. Probing the Limits of Aptamer Affinity with a Microfluidic SELEX Platform , 2011, PloS one.
[53] Siamon Gordon,et al. Neutralization of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gp120-Binding 2′F-RNA Aptamers , 2003, Journal of Virology.
[54] Rolf Backofen,et al. Variations on RNA folding and alignment: lessons from Benasque , 2007, Journal of mathematical biology.
[55] B. Sullenger,et al. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[56] Sheela M. Waugh,et al. 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.
[57] Martin Vingron,et al. A calibrated diversity assay for nucleic acid libraries using DiStRO—a Diversity Standard of Random Oligonucleotides , 2009, Nucleic acids research.
[58] L. Gold,et al. RNA ligands to human nerve growth factor. , 1995, Nucleic acids research.
[59] S. Watson,et al. Isolation and characterization of 2'-fluoro-, 2'-amino-, and 2'-fluoro-/amino-modified RNA ligands to human IFN-gamma that inhibit receptor binding. , 1997, Journal of immunology.
[60] E. Vermaas,et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin , 1992, Nature.
[61] W. Wetsel,et al. Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking , 2009, Journal of neurochemistry.
[62] N. Janjić,et al. High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[63] F. Luo,et al. Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis. , 2007, Biochemical and biophysical research communications.
[64] Zoltán Konthur,et al. Probing the SELEX Process with Next-Generation Sequencing , 2011, PloS one.
[65] J. Nevins,et al. Optimizing aptamer activity for gene therapy applications using expression cassette SELEX. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.